Evicenter
P&T meetings

Zipalertinib (CLN-081)

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417
Manufacturer
Taiho Oncology
Regulatory submission
NDA submitted February 2026
Launch
Not announced
Last updated
75 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of EGFR exon 20 insertion-mutated non-small-cell lung cancer

Economic burden and healthcare resource utilization

2 evidence topics · 3 sources

Amivantamab treatment patterns and health care resource utilization

“Mean outpatient service use was 5.87 days PPPM before amivantamab initiation and 6.79 days PPPM during amivantamab treatment.” (opens the source at this quote in a new tab)

Amivantamab plus chemotherapy economic model

“A partitioned survival model was developed based on the data from the PAPILLON trial.” (opens the source at this quote in a new tab)

“Amivantamab plus chemotherapy yielded an additional 1.12 quality-adjusted life years (QALYs) while increasing costs by $483,769.50 relative to the chemotherapy regimen, leading to an ICER of $432,401.16/QALY.” (opens the source at this quote in a new tab)

“The combination of amivantamab with chemotherapy was not cost effective at a threshold of $150,000/QALY.” (opens the source at this quote in a new tab)

“Amivantamab plus chemotherapy is unlikely to be a cost-effective option for NSCLC patients with EGFR exon 20 insertions. Reducing the cost of amivantamab may produce favorable economic outcomes.” (opens the source at this quote in a new tab)